Abstract: CONCLUSION: The rtA194T polymerase mutation is associated with partial tenofovir drug resistance and negatively impacts replication competence of HBV constructs.
Abstract: Clones harboring rtA194T showed partial resistance to tenofovir in vitro and also to LAM but remained susceptible to telbivudine and entecavir.
Abstract: In contrast, combination of rtA194T (+/- LAM resistance) with HBeAg-negative PC or BCP mutants increased the replication capacity of the drug-resistant polymerase mutants, thereby restoring the viral replication to similar levels as WT clones.
Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.
PMID: 19222103
2009
World journal of gastroenterology
Abstract: These mutations were rtV214A/rtN238T in one patient and rtA194T in the other.
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Abstract: The previously identified putative TDF-resistance mutations, rtA194T+rtL180M+rtM204V, were not detected in any individual.
Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Abstract: Conversely, against HBV cell lines expressing adefovir resistance mutations N236T and A181V, or the A194T mutant associated with resistance to tenofovir, telbivudine remained active as shown by respective fold-changes of 0.5 (N236T) and 1.0 (A181V and A194T).
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
PMID: 16801428
2006
Antimicrobial agents and chemotherapy
Abstract: The rtA194T HBV polymerase mutation recently identified in tenofovir DF-treated HIV/HBV-coinfected patients did not confer in vitro resistance to tenofovir as a single mutation or in a lamivudine-resistant viral background.
Unusual naturally occurring humoral and cellular mutated epitopes of hepatitis B virus in a chronically infected argentine patient with anti-HBs antibodies.
PMID: 16757620
2006
Journal of clinical microbiology
Abstract: Observed replacements included both humoral and/or cellular (major histocompatibility complex class I [MHC-I] and MHC-II) HBV mutated epitopes, such as S45A, P46H, L49H, C107R, T125A, M133K, I152F, P153T, T161S, G185E, A194T, G202R, and I213L.
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Abstract: Genotypic analyses from 21 of the patients revealed LAM-associated mutations, and a further two patients developed a novel mutation, rtA194T, along with LAM-resistance-associated mutations.
Abstract: In vitro, rtA194T conferred a reduced susceptibility to TDF in the presence of LAM-associated mutations.
Abstract: Phenotypic analyses revealed that constructs harbouring rtA194T combined with rtL180M and rtM204V displayed an over 10-fold increase in the IC50 for TDF compared with the wild type.
HBV mutation literature information.
PMID: 
2009
Hepatology (Baltimore, Md.)
Browser Board
Co-occurred Entities
Filtrator
ViMRT